OHSU Rare Disease Research Consortium Symposium 2015: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 18: Line 18:
|--
|--
| 4:00-5:00
| 4:00-5:00
| [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.]
| [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.], Director of preventive cardiology, Mass General Hospital
| Leveraging human knockouts to understand risk for and protection from disease
| Leveraging human knockouts to understand risk for and protection from disease
|--
|--
Line 34: Line 34:
|--  
|--  
| 6:30 to 6:35
| 6:30 to 6:35
| [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA]
| [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA], co-chair OHSU Rare Disease Research Consortium
| OHSU Rare Disease Consortium overview and objective of the symposium
| OHSU Rare Disease Consortium overview and objective of the symposium


Line 65: Line 65:
|--
|--
| 7:40 to 8:20  
| 7:40 to 8:20  
| Xiaobing Quan, M.D., Ph.D
| Xiaobing Quan, M.D., Ph.D, Executive Director, Translational Medicine at Regeneron Pharmaceuticals, Inc.
| Accelerating opportunities from discovery to clinic in rare disease research
| Accelerating opportunities from discovery to clinic in rare disease research
|--
|--

Revision as of 21:26, 30 March 2015

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954


April 7, 2015, from 4-8:30 pm at OHSU in the Joseph Vey Conference Center

11th Floor, Doernbecher Children’s Hospital
700 SW Campus Drive
Portland, OR 97239

General Info

Register for the conference

Schedule

Time Presenter Title
3:30 pm Registration
4:00-5:00 Sekar Kathiresan, M.D., Director of preventive cardiology, Mass General Hospital Leveraging human knockouts to understand risk for and protection from disease
5:00 to 6:10 Poster session and reception
6:10 to 6:20 Mary Stenzel-Poore, Ph.D., Senior Associate Dean for Research, School of Medicine Introduction
6:20 to 6:30 Laura Hays, Ph.D., Executive Director, Fanconi Anemia Research Fund Making a difference: the David Frohnmayer advocacy formula
6:30 to 6:35 Maureen Hoatlin, Ph.D.,MBA, co-chair OHSU Rare Disease Research Consortium OHSU Rare Disease Consortium overview and objective of the symposium
6:35 to 6:45 Eric Orwoll, M.D. Osteogenesis imperfecta: a brittle bone disease with well-definedmolecular pathologies but limited clinical insights and therapies
6:45 to 6:55 David Sprio, M.D., Co-founder and Chief Medical Officer, ReelDx A novel Real patient video platform that enables patients and clinicians to share rare disease phenotypes
6:55 to 7:05 Evan Shereck, M.D. Overview of the program in Pediatric Immunodeficiency Rare Disease Research Clinical Network
7:05 to 7:10 Markus Grompe, M.D. Program in Fanconi anemia
7:10 to 7:20 Cary Harding, M.D. Clinical Trials in inborn errrors of amino acid and fatty acid metabolism
7:20 to 7:40 David Ellison, M.D.
Part 1: All about that Bass: rare gene mutations and human blood pressure variation.
Part 2: How OCTRI can help rare disease research at OHSU
7:40 to 8:20 Xiaobing Quan, M.D., Ph.D, Executive Director, Translational Medicine at Regeneron Pharmaceuticals, Inc. Accelerating opportunities from discovery to clinic in rare disease research
8:20 to 8:25 Maureen Hoatlin, Ph.D, MBA Final Remarks, Action items, organizing for the future
8:25 to 8:30 iPad Giveaway